Ivabranio

Ivabradine, the active ingredient in Ivabranio, is a If channel inhibitor presented as an oral tablet for oral use. It is employed to lower heart rate in patients with chronic stable angina and in those with heart failure with reduced ejection fraction.

GNH USA supplies Ivabranio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Ivabradine acts on the cardiac sinus node to control heart rate, making it useful in several cardiovascular conditions.

Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. Heart failure with reduced ejection fraction (HFrEF): improves symptoms and decreases hospitalizations by optimizing heart rate. Stable angina during exercise: alleviates exercise‑induced chest pain through rate control.

Ivabradine may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below 50 bpm. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe bradycardia: symptomatic slowing requiring medical intervention. - Atrial fibrillation: new‑onset irregular rhythm. - Symptomatic heart block: conduction abnormalities.

When prescribing Ivabradine, several safety considerations should be observed. - Heart rate monitoring: assess baseline and periodic heart rate before and during therapy. - Concomitant beta‑blockers: avoid combined excessive bradycardia. - Strong CYP3A4 inhibitors: dose adjustment or avoidance required. - Severe hepatic impairment: contraindicated. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Ivabradine can interact with other medicines, necessitating careful review of a patient’s regimen.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Calcium‑channel blockers diltiazem or verapamil: additive bradycardic effect. - Other heart‑rate‑lowering agents (beta‑blockers, digoxin): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): reduce ivabradine efficacy. - Antihypertensives: may enhance hypotensive effect. - QT‑prolonging drugs: monitor ECG for arrhythmia risk.